CN103446062A - Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation - Google Patents
Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation Download PDFInfo
- Publication number
- CN103446062A CN103446062A CN201310374946XA CN201310374946A CN103446062A CN 103446062 A CN103446062 A CN 103446062A CN 201310374946X A CN201310374946X A CN 201310374946XA CN 201310374946 A CN201310374946 A CN 201310374946A CN 103446062 A CN103446062 A CN 103446062A
- Authority
- CN
- China
- Prior art keywords
- release
- sustained
- slow
- pioglitazone hydrochloride
- micropill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a preparing method of a compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation. A metformin hydrochloride slow-release micro-pellet is prepared from two parts of a medicated pellet core and a slow release layer, wherein the medicated pellet core is prepared from metformin hydrochloride, a filler and a binder; the slow release layer is prepared from a sustained-release material and a pore-forming agent. A pioglitazone hydrochloride slow-release micro-pellet is prepared from three parts of a blank-pellet core, a medicated layer and a slow release layer, wherein the medicated layer is prepared from pioglitazone hydrochloride, a binder and a solubilizer; the slow release layer is prepared from a sustained-release material and a pore-forming agent. The effects of lasting drug release and a stable drug release behavior can be achieved in a human body; the bioavailability is relatively improved by the stable drug release behavior; the preparation is better in curative effect, small in toxic and side effects of drugs and better in hypoglycemic effect by compound combination of the two micro-pellets. The compliance of a sufferer is improved by delivery one time in a day; better dosage regimen and curative effect are provided for diabetes patients at home and abroad.
Description
Technical field
The present invention relates to diabetes pharmaceutical technology field, especially a kind of compound formulation of compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations.
Background technology
Diabetes (diabetes) are to act on that body causes hypoinsulinism, insulin resistant etc. and a series of metabolism disorder syndromes such as the sugar that causes, protein, fat, power and water Xie Zhi by inherited genetic factors, immunologic function disorder, infected by microbes and toxin thereof, free radical toxin, Nervous and Mental Factors etc. various virulence factors.Take hyperglycemia clinically as main feature, the performance such as polyuria, polydipsia, polyphagia can appear in model case, become thin, i.e. " three-many-one-little " symptom; Diabetes (blood glucose) cause complication once control bad meeting, cause the exhaustion pathological changes at the positions such as kidney, eye, foot, and can't cure; Diabetes have become commonly encountered diseases and the frequently-occurring disease in China and even the world, and have become one of disease that M & M is the highest.Diabetes are divided into amphitypy, and the I type is insulin dependent diabetes mellitus (IDDM), and the II type is non-insulin-dependent diabetes mellitus.Wherein II type non-insulin-dependent diabetes mellitus patient is in the majority, accounts for more than 90% of patient's sum.
Metformin hydrochloride is a kind of biguanides oral antidiabetic drug, for the treatment of non-insulin-dependent diabetes mellitus.This medicine Main Function is organized outside islets of langerhans, suppresses enterocyte and absorbs glucose, increases the sensitivity of surrounding tissue to insulin, increases non-insulin and relies on gluconeogenesis function of liver.The hypoglycemic activity of biguanides does not rely on normal islet function and B cell, but increases the anerobic glycolysis of glucose, suppresses the hepatic glycogen heteroplasia, reduces blood plasma glucagon level.Pioglitazone hydrochloride is the Studies of The Insulin Sensitizer Thiazolidinediones medicine, and it can increase insulin sensitivity, reduces blood glucose.The competitive peroxide activator enzyme paraphyte receptor of such medicine energy, regulate transcribing of Insulin sensitivity gene, increase transcribing with albumen of peripheral tissues's glucose transporter 1 and glucose transporter 4 etc. synthetic, increase picked-up and the transhipment of basic glucose, thereby change insulin resistant and performance hypoglycemic activity.Metformin hydrochloride and pioglitazone hydrochloride can improve insulin resistant from different approach.When pioglitazone hydrochloride and metformin hydrochloride coupling, pioglitazone has improved the sensitivity of tissue to insulin, and the anerobic glycolysis that makes metformin hydrochloride improve surrounding tissue is better brought into play with the effect that increases surrounding tissue insulin and its receptors bind.The time limit of the two hypoglycemic activity supplements mutually, and curative effect superposes mutually, and side effect offsets.It is the good combination that treatment onset type Ⅱdiabetes mellitus especially improves insulin resistant.
Pellet capsule belongs to polydisperse system, each dosage is usually containing tens or a hundreds of micropill, micropill is compared with the slow-release tablet of a unit drug-supplying system, there are the characteristics such as concise production process, drug loading are large, good fluidity, favorable reproducibility, good stability, be widely used in the medicine sustained and controlled release preparation.The sustained-release micro-pill capsules preparation is developed rapidly in recent years, and domestic had a more report about slow release capsule preparation, and the Related products such as slow releasing capsule, enteric coated capsule are being sold on the market.But the research to compound sustained release capsules is relatively less, the domestic listing of also not ratifying compound sustained release capsules at present; The domestic existing listing of the common compound tablet of metformin hydrochloride and pioglitazone hydrochloride, its compound slow-release tablet also obtained the U.S. FDA approval in 2009, but to the domestic report that there is no of the research of compound sustained-release pellet capsule.
The patent document that number of patent application is 20101051.527.0 discloses the compound preparation of a kind of pioglitazone hydrochloride and metformin hydrochloride double-layer osmotic pump controlled-release tablet composition, on forming, structure comprises successively from the inside to the outside: the label formed by medicated layer and boosting layer, the contagion gown layer, clothing film with drug release hole, pioglitazone hydrochloride release layer and nonessential aesthstic coat, this invention adopts the double-layer osmotic pump controlled-release technology, the later stage of improving metformin hydrochloride discharges, yet preparation technology and the equipment of existing double layer osmotic pump technology are not perfect, this invention exists the feasibility problem of suitability for industrialized production, and in double-layer osmotic pump tablet, propellant adds the content that has limited every active medicine, need day to take multi-disc and just can reach effective dose, undesirable aspect raising patient medication compliance.
In view of the foregoing, now invent out a kind of compound formulation of compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations, can reach and continue in vivo release and drug release behavior effect comparatively stably, stable its bioavailability that makes of drug release behavior improves relatively, the compound recipe combination of two kinds of micropills makes its better efficacy, poisonous side effect of medicine reduces, and hypoglycemic effect is better.Within one day, be administered once and improved patient's compliance, for domestic and international diabetics provides better dosage regimen and curative effect.
Summary of the invention
The objective of the invention is in order to overcome deficiency of the prior art, a kind of compound formulation of compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations is provided, can effectively control medicine blood drug level, make blood drug level stable, and there is higher bioavailability, can improve clinical efficacy, reduce medicining times, can reach continual and steady blood sugar decreasing effect, can also improve compliance, reduce untoward reaction.
The present invention to achieve these goals, adopt following technical scheme: a kind of compound formulation of compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations, the diabecron sustained-release micropill is by forming containing pill core and slow release layer two parts, containing pill core, metformin hydrochloride, filler and binding agent, consist of, slow release layer is comprised of slow-release material and porogen, the pioglitazone hydrochloride sustained-release micropill is comprised of celphere, medicated layer and slow release layer three parts, and medicated layer is comprised of pioglitazone hydrochloride, binding agent, solubilizing agent, and slow release layer is comprised of slow-release material and porogen, the assembly percentage by weight is: metformin hydrochloride 20.0-35.0%, filler 15.0-37.5% for the diabecron sustained-release micropill, binding agent 0.2-2.5% for the diabecron sustained-release micropill, slow-release material 2.3-8.4% for the diabecron sustained-release micropill, porogen 0.01-1.0% for the diabecron sustained-release micropill, celphere 35.1-41.7%, pioglitazone hydrochloride 6.5-14.3%, binding agent 0.7-1.0% for the pioglitazone hydrochloride sustained-release micropill, solubilizing agent 0.05-0.6% for the pioglitazone hydrochloride sustained-release micropill, slow-release material 1.9-6.5% for the pioglitazone hydrochloride sustained-release micropill, porogen 0.6-2.5% for the pioglitazone hydrochloride sustained-release micropill, above each component sum by weight ratio is 100%.
The assembly percentage by weight is: metformin hydrochloride 27.0-32.0%, filler microcrystalline Cellulose 18.0-21.0% for the diabecron sustained-release micropill, filler sucrose 11.2-16.7% for the diabecron sustained-release micropill, binding agent hypromellose 1.0-2.0% for the diabecron sustained-release micropill, for the slow-release material crylic acid resin aqueous dispersion of diabecron sustained-release micropill strange 4.0-6.5% especially, porogen hypromellose 0.01-0.5% for the diabecron sustained-release micropill, celphere 36.1-39.2%, pioglitazone hydrochloride 10.0-12.5%, binding agent carboxymethyl cellulose 0.7-0.9% for the pioglitazone hydrochloride sustained-release micropill, solubilizing agent sorbitan fatty acid ester 0.1-0.3% for the pioglitazone hydrochloride sustained-release micropill, for the slow-release material crylic acid resin aqueous dispersion of pioglitazone hydrochloride sustained-release micropill strange 2.0-4.0% especially, porogen hypromellose 1.0-1.5% for the pioglitazone hydrochloride sustained-release micropill, above each component sum by weight ratio is 100%.
The assembly percentage by weight is: metformin hydrochloride 26.0-33.0%, filler microcrystalline Cellulose 17.8-22.3% for the diabecron sustained-release micropill, binding agent hypromellose 1.1-1.8% for the diabecron sustained-release micropill, slow-release material Aquacoat product Sulisi 3.5-6.1% for the diabecron sustained-release micropill, porogen hypromellose 0.01-0.32% for the diabecron sustained-release micropill, celphere 35.1-38.3%, pioglitazone hydrochloride 10.3-11.4%, binding agent methylcellulose 0.7-0.9% for the pioglitazone hydrochloride sustained-release micropill, solubilizing agent Polysorbate 0.1-0.27% for the pioglitazone hydrochloride sustained-release micropill, slow-release material Aquacoat product Sulisi 2.0-3.7% for the pioglitazone hydrochloride sustained-release micropill, porogen polyvinyl alcohol 1.0-1.4% for the pioglitazone hydrochloride sustained-release micropill, above each component sum by weight ratio is 100%.
The filler of buying from market is microcrystalline Cellulose, lactose, sucrose, starch " the wherein combination of one or more "; The binding agent of buying from market is hypromellose, polyvidone, carboxymethyl cellulose, methylcellulose, ethyl cellulose, Polyethylene Glycol, sucrose solution, sodium alginate, gelatin " the wherein combination of one or more "; The solubilizing agent of buying from market is Polysorbate, sorbitan fatty acid ester, sodium lauryl sulphate " the wherein combination of one or more "; The slow-release material of buying from market is especially strange, Aquacoat product Sulisi, cellulose acetate and matrix material " the wherein combination of one or more " of crylic acid resin aqueous dispersion; The porogen of buying from market is hypromellose, polyvinyl alcohol, sodium chloride, polyvidone, mannitol, lactose, sodium lauryl sulphate " the wherein combination of one or more ".
The invention has the beneficial effects as follows: the diameter that micropill is comprised of medicine and adjuvant is about the small entity of spherical shape of 1mm.Micropill belongs to polydisperse system, each dosage is usually containing tens or a hundreds of micropill, error or the defect of indivedual micropills in preparation is unlikely to the drug release behavior of whole preparation is affected greatly, because there is larger contact surface on medicine and gastrointestinal tract surface, absorb good and little to local zest, simultaneously, micropill is different from tablet, the former is not affected by the gastric emptying factor basically, therefore the infiltration rate of medicine is even, individual bioavailability difference is little; Micropill has the advantages such as particle diameter is even, good fluidity, difficult crushing, particularly the fine pellet core surface coatings, make location, slow release or controlled release preparation, technique is simple, can avoid other solid preparations as inhomogeneous as coatings such as tablets, may cause the risk of medicine pulse; The compound capsule formed by the micropill of different pharmaceutical, can increase medicine stability, improve curative effect, reduce poisonous side effect of medicine etc.
The metformin hydrochloride gastrointestinal absorbs rapidly, and metabolism is fast, and day medication dose is large and action time is short.Bioavailability is only 50-60%, Tmax 1-3 hour, and dosage increase to absorb reduces, and dosage is relevant without linearity to blood concentration, clinically is difficult to grasp dosage and effect; Take food and reduce absorbtivity and postpone peak time, the serum peak concentration reduces by 40%, necessary (medicine) being taken before meal use, and peak concentration changes greatly, and the patients with NIDDM of normal renal function and the patients with NIDDM of renal dysfunction can differ 1 times.Therefore be difficult to grasp dosage and effect; If make slow releasing preparation, drug release is slow, absorbs constantly, and dosage and blood drug level dependency are good, clinically is easy to grasp relation of dosage and effect.
Pioglitazone hydrochloride after oral administration, in situation, can measure pioglitazone after 30 minutes on an empty stomach in serum, within 2 hours, reaches peak concentration, and food can be by peak concentration time retardation to 3～4 hour, and then medicine is eliminated in vivo fast, and the Drug therapy window is narrower.After pioglitazone hydrochloride is prepared into to slow releasing preparation, can maintain for a long time the plasma concentration of medicine in the treatment window.Can effectively control medicine blood drug level, make blood drug level stable, and there is higher bioavailability, can improve clinical efficacy, reduce medicining times, can reach continual and steady blood sugar decreasing effect, can also improve compliance, reduce untoward reaction.
The metformin hydrochloride water solublity is fabulous, the slow release layer coating material with Aquacoat product Sulisi (Surelease) as metformin hydrochloride, and while using separately, the rete permeance property of formation is better, and the drug release effect is steady.Therefore, control the release speed of medicine by regulating the coating film thickness, make the diabecron sustained-release micropill reach desirable drug release rate.
The pioglitazone hydrochloride water solublity is bad, slow release layer coating material with Aquacoat product Sulisi (Surelease) as pioglitazone hydrochloride, while using separately, the rete permeance property formed is poor, cause the release of medicine slower, and do not have adequate thickness easily cause prominent release with drug release too fast, therefore, the present invention adds a certain amount of water-soluble polymer in the slow release layer coating solution, preferably hypromellose (HPMC-E3) is as porogen, thereby make it form the aquation passage in the clothing film and improve the clothing permeability of the membrane, make the pioglitazone hydrochloride sustained-release micropill reach desirable drug release rate.
Metformin hydrochloride adds a certain proportion of lactose containing in pill core, can prevent from making to separate out the metformin hydrochloride crystal containing the pill wicking surface containing the extremely strong water solublity due to medicine in the pill core dry run; Pioglitazone hydrochloride, due to indissoluble in water, so add a certain proportion of sodium lauryl sulphate in medicated layer, can improve drug release rate and the degree of slow-release micro-pill.
After diabecron sustained-release micropill and pioglitazone hydrochloride sustained-release micropill are mixed by a certain percentage, adopt pharmaceutically customary way, in the hard capsule of can directly packing into, can also add other pharmaceutic adjuvant and be pressed into tablet.
The present invention is that dosage and ratio are mixed in accordance with regulations, the compound slow release preparation that two kinds of different Drug combinations of hypoglycemic activity of metformin hydrochloride and pioglitazone hydrochloride are made, can bring into play its synergism, make the blood sugar decreasing effect ideal, can reduce the toxic and side effects of medicine, reduce medicining times every day, after taking medicine every day once, can reach in vivo continual and steady blood sugar decreasing effect, be conducive to improve patient's compliance, there is higher bioavailability and stable blood drug level, can effectively improve clinical efficacy.
The specific embodiment
Below in conjunction with the specific embodiment, the present invention is described in further detail:
Embodiment 1
The diabecron sustained-release micropill, by forming containing pill core and slow release layer two parts, is comprised of metformin hydrochloride, filler and binding agent containing pill core, and slow release layer is comprised of slow-release material and porogen, the pioglitazone hydrochloride sustained-release micropill is comprised of celphere, medicated layer and slow release layer three parts, and medicated layer is comprised of pioglitazone hydrochloride, binding agent, solubilizing agent, and slow release layer is comprised of slow-release material and porogen, the assembly percentage by weight is: metformin hydrochloride 20.0-35.0%, filler 15.0-37.5% for the diabecron sustained-release micropill, binding agent 0.2-2.5% for the diabecron sustained-release micropill, slow-release material 2.3-8.4% for the diabecron sustained-release micropill, porogen 0.01-1.0% for the diabecron sustained-release micropill, celphere 35.1-41.7%, pioglitazone hydrochloride 6.5-14.3%, binding agent 0.7-1.0% for the pioglitazone hydrochloride sustained-release micropill, solubilizing agent 0.05-0.6% for the pioglitazone hydrochloride sustained-release micropill, slow-release material 1.9-6.5% for the pioglitazone hydrochloride sustained-release micropill, porogen 0.6-2.5% for the pioglitazone hydrochloride sustained-release micropill, above each component sum by weight ratio is 100%.
Embodiment 2
The assembly percentage by weight is: metformin hydrochloride 27.0-32.0%, filler microcrystalline Cellulose 18.0-21.0% for the diabecron sustained-release micropill, filler sucrose 11.2-16.7% for the diabecron sustained-release micropill, binding agent hypromellose 1.0-2.0% for the diabecron sustained-release micropill, for the slow-release material crylic acid resin aqueous dispersion of diabecron sustained-release micropill strange 4.0-6.5% especially, porogen hypromellose 0.01-0.5% for the diabecron sustained-release micropill, celphere 36.1-39.2%, pioglitazone hydrochloride 10.0-12.5%, binding agent carboxymethyl cellulose 0.7-0.9% for the pioglitazone hydrochloride sustained-release micropill, solubilizing agent sorbitan fatty acid ester 0.1-0.3% for the pioglitazone hydrochloride sustained-release micropill, for the slow-release material crylic acid resin aqueous dispersion of pioglitazone hydrochloride sustained-release micropill strange 2.0-4.0% especially, porogen hypromellose 1.0-1.5% for the pioglitazone hydrochloride sustained-release micropill, above each component sum by weight ratio is 100%.
Embodiment 3
The assembly percentage by weight is: metformin hydrochloride 26.0-33.0%, filler microcrystalline Cellulose 17.8-22.3% for the diabecron sustained-release micropill, binding agent hypromellose 1.1-1.8% for the diabecron sustained-release micropill, slow-release material Aquacoat product Sulisi 3.5-6.1% for the diabecron sustained-release micropill, porogen hypromellose 0.01-0.32% for the diabecron sustained-release micropill, celphere 35.1-38.3%, pioglitazone hydrochloride 10.3-11.4%, binding agent methylcellulose 0.7-0.9% for the pioglitazone hydrochloride sustained-release micropill, solubilizing agent Polysorbate 0.1-0.27% for the pioglitazone hydrochloride sustained-release micropill, slow-release material Aquacoat product Sulisi 2.0-3.7% for the pioglitazone hydrochloride sustained-release micropill, porogen polyvinyl alcohol 1.0-1.4% for the pioglitazone hydrochloride sustained-release micropill, above each component sum by weight ratio is 100%.
Embodiment 4
The filler of buying from market is microcrystalline Cellulose, lactose, sucrose, starch " the wherein combination of one or more "; The binding agent of buying from market is hypromellose, polyvidone, carboxymethyl cellulose, methylcellulose, ethyl cellulose, Polyethylene Glycol, sucrose solution, sodium alginate, gelatin " the wherein combination of one or more "; The solubilizing agent of buying from market is Polysorbate, sorbitan fatty acid ester, sodium lauryl sulphate " the wherein combination of one or more "; The slow-release material of buying from market is especially strange, Aquacoat product Sulisi, cellulose acetate and matrix material " the wherein combination of one or more " of crylic acid resin aqueous dispersion; The porogen of buying from market is hypromellose, polyvinyl alcohol, sodium chloride, polyvidone, mannitol, lactose, sodium lauryl sulphate " the wherein combination of one or more ".
The present invention is not limited to above compound formulation, and the mutual assembly between spice, all in protection scope of the present invention.
Claims (4)
1. the compound formulation of a compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations, it is characterized in that: the diabecron sustained-release micropill is by forming containing pill core and slow release layer two parts, containing pill core, metformin hydrochloride, filler and binding agent, consist of, slow release layer is comprised of slow-release material and porogen, the pioglitazone hydrochloride sustained-release micropill is comprised of celphere, medicated layer and slow release layer three parts, and medicated layer is comprised of pioglitazone hydrochloride, binding agent, solubilizing agent, and slow release layer is comprised of slow-release material and porogen, the assembly percentage by weight is: metformin hydrochloride 20.0-35.0%, filler 15.0-37.5% for the diabecron sustained-release micropill, binding agent 0.2-2.5% for the diabecron sustained-release micropill, slow-release material 2.3-8.4% for the diabecron sustained-release micropill, porogen 0.01-1.0% for the diabecron sustained-release micropill, celphere 35.1-41.7%, pioglitazone hydrochloride 6.5-14.3%, binding agent 0.7-1.0% for the pioglitazone hydrochloride sustained-release micropill, solubilizing agent 0.05-0.6% for the pioglitazone hydrochloride sustained-release micropill, slow-release material 1.9-6.5% for the pioglitazone hydrochloride sustained-release micropill, porogen 0.6-2.5% for the pioglitazone hydrochloride sustained-release micropill, above each component sum by weight ratio is 100%.
2. the compound formulation of a kind of compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations according to claim 1, it is characterized in that: the assembly percentage by weight is: metformin hydrochloride 27.0-32.0%, filler microcrystalline Cellulose 18.0-21.0% for the diabecron sustained-release micropill, filler sucrose 11.2-16.7% for the diabecron sustained-release micropill, binding agent hypromellose 1.0-2.0% for the diabecron sustained-release micropill, for the slow-release material crylic acid resin aqueous dispersion of diabecron sustained-release micropill strange 4.0-6.5% especially, porogen hypromellose 0.01-0.5% for the diabecron sustained-release micropill, celphere 36.1-39.2%, pioglitazone hydrochloride 10.0-12.5%, binding agent carboxymethyl cellulose 0.7-0.9% for the pioglitazone hydrochloride sustained-release micropill, solubilizing agent sorbitan fatty acid ester 0.1-0.3% for the pioglitazone hydrochloride sustained-release micropill, for the slow-release material crylic acid resin aqueous dispersion of pioglitazone hydrochloride sustained-release micropill strange 2.0-4.0% especially, porogen hypromellose 1.0-1.5% for the pioglitazone hydrochloride sustained-release micropill, above each component sum by weight ratio is 100%.
3. the compound formulation of a kind of compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations according to claim 1, it is characterized in that: the assembly percentage by weight is: metformin hydrochloride 26.0-33.0%, filler microcrystalline Cellulose 17.8-22.3% for the diabecron sustained-release micropill, binding agent hypromellose 1.1-1.8% for the diabecron sustained-release micropill, slow-release material Aquacoat product Sulisi 3.5-6.1% for the diabecron sustained-release micropill, porogen hypromellose 0.01-0.32% for the diabecron sustained-release micropill, celphere 35.1-38.3%, pioglitazone hydrochloride 10.3-11.4%, binding agent methylcellulose 0.7-0.9% for the pioglitazone hydrochloride sustained-release micropill, solubilizing agent Polysorbate 0.1-0.27% for the pioglitazone hydrochloride sustained-release micropill, slow-release material Aquacoat product Sulisi 2.0-3.7% for the pioglitazone hydrochloride sustained-release micropill, porogen polyvinyl alcohol 1.0-1.4% for the pioglitazone hydrochloride sustained-release micropill, above each component sum by weight ratio is 100%.
4. the compound formulation of a kind of compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations according to claim 1, is characterized in that: from the filler of market purchase, be microcrystalline Cellulose, lactose, sucrose, starch " the wherein combination of one or more "; The binding agent of buying from market is hypromellose, polyvidone, carboxymethyl cellulose, methylcellulose, ethyl cellulose, Polyethylene Glycol, sucrose solution, sodium alginate, gelatin " the wherein combination of one or more "; The solubilizing agent of buying from market is Polysorbate, sorbitan fatty acid ester, sodium lauryl sulphate " the wherein combination of one or more "; The slow-release material of buying from market is especially strange, Aquacoat product Sulisi, cellulose acetate and matrix material " the wherein combination of one or more " of crylic acid resin aqueous dispersion; The porogen of buying from market is hypromellose, polyvinyl alcohol, sodium chloride, polyvidone, mannitol, lactose, sodium lauryl sulphate " the wherein combination of one or more ".
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374946XA CN103446062A (en) | 2013-08-26 | 2013-08-26 | Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374946XA CN103446062A (en) | 2013-08-26 | 2013-08-26 | Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103446062A true CN103446062A (en) | 2013-12-18 |
Family
ID=49729184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310374946XA Pending CN103446062A (en) | 2013-08-26 | 2013-08-26 | Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103446062A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030724A (en) * | 2015-08-20 | 2015-11-11 | 杭州成邦医药科技有限公司 | Composition of anti-diabetic drugs |
| CN111110648A (en) * | 2020-01-13 | 2020-05-08 | 新发药业有限公司 | Metformin hydrochloride controlled release tablet |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726912A (en) * | 2005-07-25 | 2006-02-01 | 天津药物研究院 | Slow release capsule of compound metformin pyrrolidone and preparation method |
| CN101411702A (en) * | 2008-11-29 | 2009-04-22 | 河南大学 | Nefopam hydrochloride naproxen sodium compound sustained-release preparation and preparation method thereof |
-
2013
- 2013-08-26 CN CN201310374946XA patent/CN103446062A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726912A (en) * | 2005-07-25 | 2006-02-01 | 天津药物研究院 | Slow release capsule of compound metformin pyrrolidone and preparation method |
| CN101411702A (en) * | 2008-11-29 | 2009-04-22 | 河南大学 | Nefopam hydrochloride naproxen sodium compound sustained-release preparation and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030724A (en) * | 2015-08-20 | 2015-11-11 | 杭州成邦医药科技有限公司 | Composition of anti-diabetic drugs |
| CN111110648A (en) * | 2020-01-13 | 2020-05-08 | 新发药业有限公司 | Metformin hydrochloride controlled release tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1891229B (en) | Medicinal composition for preventing or treating metabolic syndrome | |
| CN104146976B (en) | Heavy-load valproic acid drug sustained release tablet and preparation method thereof | |
| WO2011063732A1 (en) | Paliperidone double-layered osmotic pump controlled release tablet and preparation method thereof | |
| CN103417496A (en) | Method for preparing metformin hydrochloride controlled-release pellet preparation | |
| CN103285398A (en) | Compound preparation containing DPP-IV (dipeptidyl peptidase-IV) inhibitor and type-II diabetes medicine and preparation method thereof | |
| CN106727404A (en) | Diabecron sustained-release tablet and preparation method thereof | |
| CN112137990A (en) | Epalrestat sustained-release preparation and preparation method thereof | |
| CN103446063B (en) | A kind of compound formulation of compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations and preparation technology | |
| CN103976997A (en) | Hypoglycemic compound sustained-release capsule and preparation method thereof | |
| CN103520129A (en) | Montelukast sodium pulse release preparation | |
| JP7083855B2 (en) | Glucose pellets, their preparation methods and their use | |
| CN103446062A (en) | Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation | |
| CN1331470C (en) | Method for preparing high stripping-degree hautriwaic glipizide capsule | |
| CN103230381B (en) | Zolpidem tartrate time-selecting pulse sustained-release pellet and preparation method thereof | |
| CN103432081A (en) | Method for compounding drug-containing pellet core of metformin hydrochloride controlled-release pellet preparation | |
| CN1985823A (en) | Slow released preparation containing metformin hydrochloride and rosiglitazone and its preparing process | |
| CN103432128B (en) | A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer | |
| CN103432129B (en) | A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations | |
| CN103417495A (en) | Method for preparing pioglitazone hydrochloride controlled-release pellet preparation slow-release layer | |
| CN103462903B (en) | A kind of preparation technology of pioglitazone hydrochloride sustained-release pellet preparations | |
| CN101756981A (en) | Brufen loratadine pseudoephedrine release preparation and preparation method thereof | |
| CN105476995A (en) | Metformin-acipimox compound sustained-release capsule and preparing method | |
| CN101168060B (en) | Stable medicinal composition containing biguanide and sulfonylurea and preparation method thereof | |
| CN110575443A (en) | Doxofylline sustained release tablet and preparation method thereof | |
| CN101683340A (en) | Sustained-release preparation of compound metformin hydrochloride rosiglitazone and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131218 |
|
| RJ01 | Rejection of invention patent application after publication |